Sanofi and Innate Pharma team up on anticancer ADCs

Sanofi ($SNY) has reached out to its French neighbor Innate Pharma to collaborate on armed antibody treatments, borrowing the biotech's technology to craft new treatments for cancer and inflammatory disease. Under the deal, Sanofi will use Innate's targeting method to hone antibody treatments designed to deliver drug payloads without affecting healthy tissues. Neither side disclosed financial details. More

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.